Investment Snapshot
Elevara Medicines
Evidence depth
Strong
RA biology, fibroblast pathway, SOC landscape, regulatory precedent
Adequate
Phase 1b clinical signals, competitive positioning
Thin
proprietary CMC, payer feasibility specifics, manufacturing scale
Diligence readiness
Adequate for institutional review; Phase 2 readout-pending diligence cycle
Gap-bounded
4 open questions require sponsor disclosure or proprietary access
Open questions
4 questions requiring sponsor disclosure
- Phase 2 enrollment velocity vs. RA trial precedent
- Combination-therapy dosing strategy with methotrexate + TNFi
- FLS-selectivity durability across RA clinical heterogeneity
- Cross-border IP coordination with Teijin Pharma
Comparable benchmarks
RA treatment-resistant landscape · biologic and JAKi comparators
Foster Rx renders evidence. The investment decision is yours.
Investor Diligence Report
Elevara Medicines is a clinical-stage biotech advancing ELV001, described publicly as
"a first-in-class oral CDK4/6 inhibitor that selectively targets fibroblast-like synoviocytes (FLS)
— a key driver of RA pathology — without suppressing the immune system."[1]
Diligence focuses on four dimensions: (i) the mechanism case — whether FLS-selectivity holds at
doses that drive clinical effect, with Phase 1b having shown "favorable safety and tolerability,
alongside encouraging early efficacy signals"[1];
(ii) the START-SYNERGY Phase 2 design (placebo-controlled, three ascending dose levels, 180
patients planned with DAS28-CRP primary endpoint at week 12, US + South Africa sites)[2];
(iii) the competitive landscape against approved JAK inhibitors (Xeljanz, Olumiant, Rinvoq —
all under FDA boxed warning for cardiovascular and malignancy risk) and biologic DMARDs (Humira,
Orencia, Kevzara), with FLS-selective non-immunosuppression as the structural differentiator; and
(iv) the cross-border in-licensing posture — exclusive global rights from Teijin Pharma
(Japan) into a UK-headquartered NewCo backed by Forbion + Sofinnova-led $70M Series A
(22 October 2025)[1,3,4].
§01 · Identity & biology
CompleteCompany: Elevara Medicines Limited, headquartered in London, UK[1]. Lead asset ELV001 is publicly described as "a first-in-class oral CDK4/6 inhibitor that selectively targets fibroblast-like synoviocytes (FLS)"[1]. Mechanism rationale: CDK4/6 → Rb phosphorylation → cell-cycle G1/S progression. In rheumatoid arthritis, synovial fibroblasts proliferate aberrantly and drive local cytokine production, pannus formation, and joint destruction. Pharmacological CDK4/6 inhibition arrests this fibroblast proliferation without the immunosuppressive effects of cytokine blockade, providing a mechanistically orthogonal axis to the JAK inhibitor and TNF inhibitor classes.
source · forbion.com · DDW
Patient target. Phase 2 START-SYNERGY enrolls RA patients with "inadequate response to methotrexate and TNF inhibitors"[2] — a clinically defined treatment-resistant population that current SOC addresses imperfectly via JAK inhibitor switching or biologic cycling. The CMO Professor Dominique Baeten frames the positioning: "By targeting the synovial fibroblast rather than immune cells, ELV001 is uniquely positioned to work with approved immunomodulators."[4]
source · NCT07409103 · DDW
Figure A · ELV001 mechanism · FLS-selective CDK4/6 arrest, non-immunosuppressive
[1] Forbion · "Forbion Co-Leads $70 Million Series A Financing for Elevara Medicines" · 22 October 2025. forbion.com (accessed 26 May 2026).
[2] ClinicalTrials.gov · NCT07409103 · START SYNERGY Phase 2 trial registration. clinicaltrials.gov/study/NCT07409103.
[3] Sofinnova Partners · "Elevara Medicines Raises USD70 Million Series A" · October 2025. sofinnovapartners.com.
[4] Drug Discovery World · "Elevara Medicines raises $70m for RA Phase II trial" · October 2025. ddw-online.com.
§02 · Composite scoring
Complete · methodology-attributedFoster Rx Capital composite renders under methodology_id: foster_rx.composite_score.v1. Each axis carries a pattern-anchored estimate with explicit gap caveats; axes are not a substitute for primary diligence.
methodology · foster_rx.composite_score.v1
Figure B · Composite profile · v1 methodology
Mechanism plausibility — material. CDK4/6 biology is one of the most well-published cell-cycle axes — three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are FDA-approved in HR+/HER2− metastatic breast cancer[5]. The FLS-selectivity claim differentiates Elevara from that oncology heritage; the differentiation rests on tissue-distribution biology of CDK4/6 expression in proliferative fibroblasts vs. quiescent immune cells. Baeten's published body of work on synovial fibroblast biology in inflammatory arthritis is the anchoring scientific lineage[6].
composite axis · mechanism plausibility
Clinical evidence — workable. Phase 1b reported as "favorable safety and tolerability, alongside encouraging early efficacy signals"[1] — characteristic anodyne language without quantitative endpoints. Phase 2 START-SYNERGY design is statistically robust (DAS28-CRP primary at week 12, three ascending dose levels vs. placebo, 180 patients extensible to 220, triple-masked)[2]. The diligence question is enrollment velocity — recruiting MTX+TNFi-refractory RA patients across US + South Africa sites at the pace needed for April 2027 primary completion.
composite axis · clinical evidence
Capital structure — material. $70M Series A co-led by Forbion and Sofinnova Partners is a tier-1 European/transatlantic syndicate signal[1,3]. Monograph Capital as founding investor (with Weatherden) provides UK biotech-formation continuity. Board composition — Maina Bhaman (Sofinnova) + Vanessa Carle (Forbion) + Tim Funnell (Monograph) + Gijs van den Brink (Independent) — is consistent with institutional-grade Phase 2 governance.
composite axis · capital structure
SOC differentiation — material. Add-on positioning to methotrexate + TNF inhibitor is structurally different from the JAK inhibitor switch-pathway (Xeljanz, Olumiant, Rinvoq), the biologic-cycling pathway (Humira → Kevzara → Orencia), and the IL-6 pathway (Actemra). The FLS-targeting mechanism creates an orthogonal axis to all three. If the Phase 2 readout shows meaningful DAS28-CRP improvement on top of standard care with manageable safety, the commercial framing is expansion-of-line rather than displacement-of-line — historically a smoother go-to-market path in RA.
composite axis · SOC differentiation
[5] FDA Drugs · CDK4/6 inhibitor approvals (palbociclib 2015, ribociclib 2017, abemaciclib 2017) for HR+/HER2− metastatic breast cancer. fda.gov/drugs.
[6] PubMed · Baeten lineage on synovial fibroblast biology in inflammatory arthritis. pubmed.ncbi.nlm.nih.gov.
§03–§06 · Drugability / probe chemistry / chemical starting points / selectivity
Evidence insufficient · proprietary CMC
Gap · proprietary CMC outside public domain
INACCESSIBLE_DATA · sponsor disclosure under CDA would close
These four sections render the molecular drugability axes (CanSAR drugability score, Probe Miner chemistry, lead-optimization starting points, kinase selectivity profile). Elevara has disclosed ELV001 as an oral CDK4/6 inhibitor but the structural class, IC50 against CDK4/6 vs. off-target kinases, oral bioavailability fraction, and the in-licensed Teijin patent claims are not in the public domain. Composite-score methodology flags these as
insufficient rather than not_applicable — sponsor disclosure under CDA would close the gap.
§07 · ADMET / DMPK
Complete · framework-levelOral CDK4/6 inhibitor class context. The three FDA-approved CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) all show oral bioavailability in the 30-60% range and CYP3A4-mediated metabolism with class-characteristic neutropenia at oncology doses[5]. In RA, the dose envelope is materially lower than oncology (per ELV001 Phase 2 doses 25-125mg vs. palbociclib 125mg-only oncology dose[2,5]), suggesting the developer is targeting a different efficacy-toxicity tradeoff. ELV001 Phase 1b safety reported as favorable; specific PK parameters not publicly disclosed.
source · FDA labeling · NCT07409103
The diligence question — DDIs with concomitant RA medications. START-SYNERGY enrolls patients on stable methotrexate (15-25mg/week oral)[2]. CDK4/6 inhibitor + MTX coadministration has limited published precedent — neither overlap in metabolism (CDK4/6 inhibitors via CYP3A4; MTX renal clearance) nor overlap in toxicity (CDK4/6: neutropenia/fatigue; MTX: hepatotoxicity, mucositis) flag obvious interaction concerns, but the Phase 2 trial's secondary endpoints on liver function and pharmacokinetics will provide first systematic data.
computed · Foster Rx synthesis
§08 · Pathways · CDK4/6 → Rb → E2F → cell cycle
CompleteCDK4/6 (cyclin-dependent kinases 4 and 6) partner with D-type cyclins to phosphorylate retinoblastoma protein (Rb). Hypophosphorylated Rb sequesters E2F transcription factors; phosphorylation releases E2F to drive G1→S phase transition genes. In RA synovial fibroblasts, the CDK4/6-Rb-E2F axis is aberrantly activated, driving the FLS proliferation that builds pannus tissue and destroys cartilage[6,7]. ELV001 pharmacologically halts FLS proliferation at the G1/S checkpoint. The pathway is well-published in both oncology (where CDK4/6 inhibitors are approved in HR+ breast cancer) and rheumatology (FLS as a therapeutic target has been proposed for over a decade in the academic literature).
source · PubMed · published Rb/E2F biology
[7] PubMed · "fibroblast-like synoviocyte CDK4 rheumatoid" literature search. pubmed.ncbi.nlm.nih.gov.
§09 · Genetic evidence · RA risk loci
Complete · framework-levelRA has one of the most thoroughly mapped genetic architectures in autoimmune disease: HLA-DRB1 shared-epitope alleles, PTPN22, STAT4, CTLA4, TRAF1-C5, and ~100+ additional loci identified by GWAS confer susceptibility[7]. The genetic evidence informs disease-mechanism understanding but does not directly support or refute ELV001's mechanism — RA risk loci concentrate on immune cell biology (the JAK/STAT, T-cell, B-cell axes that JAKi and biologics target), whereas ELV001 targets the downstream tissue effector (FLS proliferation). This is not a weakness — it is a different therapeutic logic — but it does mean the "genetic validation" frame typical of newer targets does not anchor ELV001's case in the standard way.
source · published RA GWAS · Open Targets
§11 · Expression · CDK4/6 in FLS vs. immune cells
Complete · framework-levelThe selectivity claim. ELV001's positioning rests on the proposition that CDK4/6 inhibition affects proliferating fibroblasts (FLS in inflamed RA synovium) more than quiescent or slowly-cycling immune cells (resting T cells, memory B cells). This is biologically plausible: CDK4/6 is rate-limiting for cells in active G1→S transition, less constraining for cells in extended G0 quiescence. The Phase 1b safety profile — reported as favorable without immune-cell toxicity flags[1] — is consistent with this selectivity narrative.
computed · Foster Rx synthesis
The diligence question — selectivity durability. Chronic dosing (12-week Phase 2, with extension to 220 patients planned) is a more stringent test than the Phase 1b time horizon. RA patients are immune-modulated by their existing MTX + TNFi regimen; the question is whether ELV001 at 75mg or 125mg daily creates any incremental immune signal over 12 weeks of dosing. The Phase 2 secondary endpoints on lab parameters and adverse events will provide first systematic data; the Phase 1b data is suggestive but the sample is small.
flagged · Phase 2 readout-dependent
§14 · Scholarly evidence · FLS biology in RA
CompleteFibroblast-like synoviocytes as a therapeutic target in RA have a substantial peer-reviewed literature base going back two decades[6,7]. Prior approaches have included targeting FLS-derived cytokines (IL-6 inhibition via Actemra, IL-1 inhibition via Kineret), FLS surface markers, and FLS-derived matrix metalloproteinases. Direct pharmacological arrest of FLS proliferation via cell-cycle inhibition is, to public knowledge, novel as a clinical approach in RA. The literature anchors the mechanism rationale without establishing clinical precedent.
source · PubMed · Baeten + Firestein FLS lineage
§15 · Investigator network & institutional anchor
CompleteClinical leadership. Professor Dominique Baeten, MD, PhD — Chief Medical Officer. Internationally recognized rheumatologist with peer-reviewed body of work on synovial inflammation, spondyloarthritis, and inflammatory arthritis biology. Anchors the scientific case in independently-credentialed expertise rather than purely industrial KOL recruitment[1,4].
source · forbion.com · DDW
Trial footprint. START-SYNERGY is a multi-site Phase 2 with sites disclosed in the United States (Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania, Texas — approximately 20+ US cities) and South Africa (8 cities across multiple provinces)[2]. The transatlantic + emerging-market site distribution is consistent with Phase 2 enrollment efficiency in MTX+TNFi-refractory RA — South Africa contributes both scale and faster regulatory turnaround. Specific site list and per-site enrollment requires direct disclosure beyond the ClinicalTrials.gov record.
source · NCT07409103 · sites field
Figure E · START-SYNERGY trial design · 4 arms (placebo + 25/75/125mg), DAS28-CRP primary endpoint at week 12
| Population segment | Approximate US size · framework estimate | Status | Source |
|---|---|---|---|
| Total US RA prevalence | ~1.3M adults | Established | [10] |
| Of which biologic-treated | ~30-40% of diagnosed/treated population | Framework | [8,10] |
| Of biologic-treated, refractory at first biologic | ~30% inadequate response within 12 months | Framework | [8] |
| MTX + TNFi-refractory (Phase 2 eligible) | The constrained segment ELV001 enrolls — high unmet need | Target | [2] |
| Phase 3 expansion candidates | Broader treatment-resistant + line-extensions to chronic inflammatory + women's health | Planned | [1] |
§16 · Competitive landscape · RA SOC and treatment-resistant comparators
CompleteThe RA treatment cascade is well-established. First-line conventional synthetic DMARDs (methotrexate; alternatives sulfasalazine, leflunomide, hydroxychloroquine) per ACR/EULAR guidelines[8]. Inadequate response triggers TNF inhibitor addition (adalimumab/Humira, etanercept/Enbrel, infliximab/Remicade and biosimilars). Subsequent inadequate response opens the JAK inhibitor pathway (tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq) or the biologic-cycling pathway (abatacept/Orencia, sarilumab/Kevzara, rituximab/Rituxan, tocilizumab/Actemra). Table A enumerates the comparator set.
source · ACR/EULAR guidelines · FDA labeling
Figure D · RA treatment cascade with ELV001 add-on positioning at the treatment-resistant gap
| Comparator | Mechanism | Approval year | Position vs. Elevara | Source |
|---|---|---|---|---|
| Humira (adalimumab) | TNF-α inhibitor · biologic | 2002 | SOC reference; ELV001 enrolls TNFi-refractory patients | [8] |
| Xeljanz (tofacitinib) | Pan-JAK inhibitor · oral | 2012 | Boxed warning (MACE, malignancy) post-ORAL Surveillance[9] | [8,9] |
| Olumiant (baricitinib) | JAK1/2 inhibitor · oral | 2018 | Same class boxed warning; switch-pathway competitor | [8,9] |
| Rinvoq (upadacitinib) | JAK1-selective · oral | 2019 | Most-prescribed JAKi for RA; same class boxed warning | [8,9] |
| Orencia (abatacept) | T-cell co-stim modulator · biologic | 2005 | Biologic-cycling alternative; non-immunosuppressive vs. ELV001 is the structural diff | [8] |
| Kevzara (sarilumab) | IL-6R antagonist · biologic | 2017 | IL-6 axis; ELV001 targets downstream tissue effector | [8] |
| ELV001 (Elevara) | CDK4/6 inhibitor · oral · FLS-selective | Ph 2 | First-in-class add-on · non-immunosuppressive | [1,2] |
Figure G · Competitive 2×2 · Elevara in upper-right white space (oral, non-immunosuppressive)
Strategic interpretation. The competitive set bifurcates structurally. The JAK inhibitor class (Xeljanz/Olumiant/Rinvoq) carries an FDA boxed warning for major adverse cardiovascular events, malignancy, thrombosis, and mortality following the ORAL Surveillance comparator study[9] — creating real prescribing friction. The biologic set (Humira, Orencia, Kevzara, Actemra, Rituxan) has cleaner safety but requires injectable administration and faces a complex biosimilar competitive picture. ELV001's oral, non-immunosuppressive, add-on positioning is structurally orthogonal to both — if Phase 2 efficacy confirms, the commercial framing is line-extension over either switching or cycling.
computed · Foster Rx synthesis
[8] ACR · Rheumatoid Arthritis Guideline. rheumatology.org/practice-quality/clinical-support/clinical-practice-guidelines/rheumatoid-arthritis.
[9] FDA · Drug Safety Communication · boxed warning for JAK inhibitors following ORAL Surveillance (September 2021). fda.gov/drugs/drug-safety-and-availability.
§17 · Patents landscape · CDK4/6 + FLS-targeting IP
Complete · framework-levelCDK4/6 IP class is densely populated by the established oncology assignees (Pfizer for palbociclib/Ibrance; Novartis for ribociclib/Kisqali; Eli Lilly for abemaciclib/Verzenio). For RA / FLS-targeting positioning, the load-bearing IP is the in-licensed Teijin Pharma patent estate covering ELV001 composition-of-matter and methods of use[1]. Counsel-led primary search at USPTO (Teijin Pharma assignee variants), JPO (Japanese filings), EPO (European), and WIPO (PCT applications) is required for asset-specific FTO conclusions.
source · USPTO · WIPO framework
Figure C · Cross-border in-licensing · Teijin Japan → Elevara UK NewCo → global markets
The diligence question — Teijin / Elevara IP coordination. Cross-border in-licensing of a clinical-stage asset from a publicly-traded Japanese pharma to a UK NewCo creates standard IP-coordination questions: (i) who controls prosecution strategy across jurisdictions; (ii) how milestone-and-royalty economics flow back to Teijin; (iii) what reversion rights exist on failure; (iv) what's the Teijin-side patent estate breadth (composition-of-matter, method-of-use, manufacturing process). Not addressable from public materials; counsel-led primary review of the in-license agreement is the diligence path.
flagged · counsel review required
Figure F · CDK4/6 patent landscape · oncology approvals as comparable anchors + FLS-targeting RA branch via Teijin in-license
§18 · Regulatory precedent · RA add-on therapy framework
Complete · framework-levelRA add-on therapy regulatory pathway. The FDA RA approval framework is well-established and the Phase 2 → Phase 3 → approval path is mature. The DAS28-CRP primary endpoint at week 12 is the conventional Phase 2 surrogate; ACR20/50/70 response rates are standard secondary endpoints; the Phase 3 envelope typically requires demonstration of structural benefit (radiographic progression) plus symptomatic improvement on top of background SOC for an add-on label. ELV001's add-on positioning to MTX + TNFi means the Phase 3 design will compare ELV001 + SOC vs. placebo + SOC, with the SOC arm not switched off.
source · FDA RA guidance · ACR/EULAR endpoints
Class precedent — CDK4/6 in non-oncology indications. The CDK4/6 inhibitor class has no FDA-approved non-oncology indications as of accessed date. ELV001's pathway is therefore first-in-class for a new indication; this is a feature (white-space positioning) rather than a bug (no class precedent to follow), but it does mean the regulatory dialogue will be early in defining acceptable safety thresholds at chronic dosing in a non-oncology population.
source · FDA approvals database
§22 · Standard of care & unmet need · treatment-resistant RA
CompleteMTX-refractory + TNFi-refractory RA — the patient population ELV001 enrolls in Phase 2 — is the segment where current SOC most clearly underperforms. After biologic cycling and JAK inhibitor switching, a non-trivial fraction of patients remain symptomatic with progressing structural damage, and the safety budget for adding more immunosuppression narrows. This is where a non-immunosuppressive add-on creates clear unmet-need framing[8].
source · ACR/EULAR · published RA epidemiology
Market sizing context. Approximately 1.3M Americans live with rheumatoid arthritis; global prevalence ~17.6M per 2019 GBD[10]. Treatment-resistant share varies by source but is consistently estimated in the 20–40% range of biologic-treated patients. ELV001's Phase 2 enrollment criteria target the more constrained end of that range (MTX + TNFi-refractory specifically). Phase 3 expansion candidates likely include broader treatment-resistant populations and the planned line extensions to inflammatory and women's-health indications.
source · GBD 2019 · ACR registry data
[10] Global Burden of Disease 2019 · Rheumatoid arthritis prevalence estimates. healthdata.org.
§23 · Payer feasibility & commercial economics
Evidence insufficient · pre-approval framing only
Gap · pricing analogue not yet established
TIER_3_PARTNER_PENDING · partner: MMIT (payer-coverage and reimbursement analytics) · supplemented by METHODOLOGY_GAP (pricing-analogue methodology pending Phase-2 readout)
Payer feasibility for ELV001 cannot be modeled with confidence pre-Phase-2 readout. Reference points: oral RA JAKi (Xeljanz, Olumiant, Rinvoq) carry list prices around $5,000-7,000/month in the US market with biosimilar TNFi pressure on the channel. CDK4/6 inhibitor oncology pricing ($10,000-14,000/month for palbociclib/ribociclib/abemaciclib) is not a relevant analogue — those are RA-irrelevant orphan-population economics. The most likely framing is at the JAKi end of the band, but actual pricing and payer-access conversations are post-Phase-3 conversations. Foster Rx renders this as bounded gap rather than estimating a price.
§24 · Funding & institutional anchors
CompleteSeries A · $70M · 22 October 2025. Co-led by Forbion and Sofinnova Partners, with founding investor Monograph Capital and Weatherden participating[1,3]. Forbion is a European life-sciences specialist with extensive RA/inflammatory experience; Sofinnova Partners is a tier-1 transatlantic life-sciences investor. Monograph Capital is a UK-based biotech-formation investor. Weatherden is identified as company founder/co-formation partner. The syndicate structure is institutional-grade and consistent with Phase 2 → Phase 3 progression capital.
source · Forbion · Sofinnova
| Role | Investor | Notes | Source |
|---|---|---|---|
| Series A co-lead | Forbion | European life-sciences specialist · Vanessa Carle joins Board | [1] |
| Series A co-lead | Sofinnova Partners | Transatlantic life-sciences · Maina Bhaman joins Board | [3] |
| Founding investor | Monograph Capital | UK biotech-formation · Tim Funnell on Board | [1] |
| Founding partner | Weatherden | Company founder partner · UK | [1] |
| Independent | Gijs van den Brink | Independent Director on Board | [1] |
| $70M Series A · 22 October 2025 | Funds Phase 2 START-SYNERGY + exploratory pipeline expansion | ||
§25 · Disease burden & sociodemographic context
Complete · framework-levelRheumatoid arthritis affects ~1.3M US adults and ~17.6M individuals globally (GBD 2019)[10]. Female:male prevalence ratio approximately 3:1; peak onset in fifth and sixth decades, with material early-adult onset cohort. Functional impairment, work loss, and joint replacement surgery aggregate into a high direct-and-indirect cost burden. Treatment-resistant RA disproportionately drives long-term cost; ELV001's targeted positioning at this subpopulation is well-aligned to where unmet need and willingness-to-pay co-locate.
source · GBD 2019 · ACR
§13 · §20 · §21 · Sections requiring sponsor disclosure
Evidence insufficient · NDA-bounded
Gap · proprietary cell-line, GMP, and commercial data outside public domain
INACCESSIBLE_DATA · sponsor disclosure under CDA · §13 composite includes TIER_3_PARTNER_PENDING · partner: Elucidata (multi-omics depth)
Cell-line essentiality / target validation models (§13), GMP CMC and supply chain build-out (§20), economic commercialization model with TPP and competitor pricing (§21) are not in the public domain. Sponsor disclosure under CDA would close these gaps. Foster Rx does not estimate pricing or manufacturing scale from public data alone — those are post-CDA diligence-cycle inputs. §13 cell-line essentiality additionally awaits Elucidata partner activation for systematic multi-omics depth.
Source manifest · consolidated
- Forbion · "Forbion Co-Leads $70 Million Series A Financing for Elevara Medicines" (22 October 2025) — forbion.com
- ClinicalTrials.gov · NCT07409103 · START-SYNERGY Phase 2 trial registration — https://clinicaltrials.gov/study/NCT07409103
- Sofinnova Partners · "Elevara Medicines Raises USD70 Million Series A" — sofinnovapartners.com
- Drug Discovery World · "Elevara Medicines raises $70m for RA Phase II trial" (October 2025) — ddw-online.com
- FDA Drugs · CDK4/6 inhibitor approvals (palbociclib 2015 · ribociclib 2017 · abemaciclib 2017) — https://www.fda.gov/drugs
- PubMed · Baeten synovial fibroblast biology in inflammatory arthritis — pubmed.ncbi.nlm.nih.gov
- PubMed · "fibroblast-like synoviocyte CDK4 rheumatoid" — pubmed.ncbi.nlm.nih.gov
- American College of Rheumatology · Rheumatoid Arthritis Clinical Practice Guideline — rheumatology.org
- FDA · Drug Safety Communications · JAK inhibitor boxed warning following ORAL Surveillance (September 2021) — fda.gov/drugs/drug-safety-and-availability
- Global Burden of Disease 2019 · Rheumatoid arthritis fact sheet — healthdata.org
- BioSpace · "Elevara Medicines Raises $70 Million Series A" (October 2025) — biospace.com
- USPTO Patent Public Search · Teijin Pharma CDK4/6 patent family search framework — ppubs.uspto.gov
Force11 citation block · v1.6 B.2 envelope extension
[1] Forbion Co-Leads $70 Million Series A Financing for Elevara Medicines
- authors
- Forbion
- persistent_id
- https://forbion.com/news-insights/news/forbion-co-leads-70-million-series-a-financing-for-elevara-medicines-to-advance-phase-2-rheumatoid-arthritis-trial-and-expand-pipeline/
- publication_date
- 2025-10-22
- title
- Forbion Co-Leads $70 Million Series A Financing for Elevara Medicines
- publisher
- Forbion
- version
- as accessed 26 May 2026
- access_url
- https://forbion.com/news-insights/news/forbion-co-leads-70-million-series-a-financing-for-elevara-medicines-to-advance-phase-2-rheumatoid-arthritis-trial-and-expand-pipeline/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[2] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT07409103
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT07409103
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[3] Elevara Medicines Raises USD70 Million Series A
- authors
- Sofinnova Partners
- persistent_id
- https://sofinnovapartners.com/news/elevara-medicines-raises-usd70-million-series-a-to-advance-phase-2-rheumatoid-arthritis-trial-and-expand-pipeline
- publication_date
- accessed 26 May 2026
- title
- Elevara Medicines Raises USD70 Million Series A
- publisher
- Sofinnova Partners
- version
- as accessed 26 May 2026
- access_url
- https://sofinnovapartners.com/news/elevara-medicines-raises-usd70-million-series-a-to-advance-phase-2-rheumatoid-arthritis-trial-and-expand-pipeline
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[4] Elevara Medicines raises $70m for RA Phase II trial
- authors
- Drug Discovery World
- persistent_id
- https://www.ddw-online.com/elevara-medicines-raises-70-million-for-ra-phase-ii-trial-38186-202510/
- publication_date
- accessed 26 May 2026
- title
- Elevara Medicines raises $70m for RA Phase II trial
- publisher
- Drug Discovery World
- version
- as accessed 26 May 2026
- access_url
- https://www.ddw-online.com/elevara-medicines-raises-70-million-for-ra-phase-ii-trial-38186-202510/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[5] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.fda.gov/drugs
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- U.S. Food and Drug Administration
- version
- as accessed 26 May 2026
- access_url
- https://www.fda.gov/drugs
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[6] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://pubmed.ncbi.nlm.nih.gov/?term=Baeten+synovial+fibroblast+arthritis
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- U.S. National Library of Medicine · PubMed
- version
- as accessed 26 May 2026
- access_url
- https://pubmed.ncbi.nlm.nih.gov/?term=Baeten+synovial+fibroblast+arthritis
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[7] fibroblast-like synoviocyte CDK4 rheumatoid
- authors
- [not specified in source]
- persistent_id
- https://pubmed.ncbi.nlm.nih.gov/?term=fibroblast-like+synoviocyte+CDK4+rheumatoid
- publication_date
- accessed 26 May 2026
- title
- fibroblast-like synoviocyte CDK4 rheumatoid
- publisher
- U.S. National Library of Medicine · PubMed
- version
- as accessed 26 May 2026
- access_url
- https://pubmed.ncbi.nlm.nih.gov/?term=fibroblast-like+synoviocyte+CDK4+rheumatoid
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[8] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.rheumatology.org/practice-quality/clinical-support/clinical-practice-guidelines/rheumatoid-arthritis
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- American College of Rheumatology
- version
- as accessed 26 May 2026
- access_url
- https://www.rheumatology.org/practice-quality/clinical-support/clinical-practice-guidelines/rheumatoid-arthritis
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[9] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.fda.gov/drugs/drug-safety-and-availability
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- U.S. Food and Drug Administration
- version
- as accessed 26 May 2026
- access_url
- https://www.fda.gov/drugs/drug-safety-and-availability
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[10] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.healthdata.org/research-analysis/diseases-injuries-risks/factsheets/2019-rheumatoid-arthritis-level-3-disease
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- Institute for Health Metrics and Evaluation (IHME)
- version
- as accessed 26 May 2026
- access_url
- https://www.healthdata.org/research-analysis/diseases-injuries-risks/factsheets/2019-rheumatoid-arthritis-level-3-disease
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
Translational Confidence Score · v1.5 decomposition
TCS · computation pending
Section coverage
Share of the 25 brief sections at
CERTIFIED status — vs. EVIDENCE_INSUFFICIENT, NO_DATA_AVAILABLE, PARTIAL. Counts honest-emptiness gap_explanations as accounted-for, not as silent drops.pending
Posterior tightness
Calibration variance per certified claim — derived from L̂(Gₜ) tracked against the resolved outcome subset. Tightens as |Oₜ| (the outcome history) grows.
pending
Methodology quality
Aggregate validation grade across registered methodologies M — anchored on Inv₆ non-regression gate (validation against held-out fixtures before registration in M_t).
pending
Reproducibility signal
Outcome-anchoring fidelity — how reliably prediction-outcome pairs (c, o) in O reconcile within expected lag τ. Slow-timescale measurement; meaningful once outcome corpus depth is non-trivial.
pending
Envelope · publicly verifiable
- Methodology manifest
- foster_rx.composite_score.v1 · foster_rx.evidence_bounding.v1
- Source manifest hash
- sha256:4e7c…live-demo · 12 sources · 0 fabricated
- Status
- 25 sections · 13 complete · 3 EI bundles (4 small-mol axes + payer + cell-line/GMP/commercial)
- Signature
- ed25519:demo-preview · pre-publication · not certified
- Date
- 26 May 2026 · live demo rendering
Diligence Snapshot
Metro International Biotech
Evidence depth
Strong
NAD mechanism, indication rationale, Sinclair-lineage science
Adequate
competitive program tracking, regulatory precedent
Thin
proprietary CMC, payer feasibility, commercial economics
Validation readiness
Mechanism well-validated across multiple indications
Gap-bounded
Clinical-stage exposure varies by indication
Open questions
3 questions requiring sponsor disclosure
- Differentiation depth vs. Elysium / ChromaDex NAD-class programs
- Regulatory pathway for AKI and long-COVID indications
- EdenRoc holding structure economic implications
Competitive landscape
NAD-precursor therapeutic category
Foster Rx renders evidence. The licensing decision is yours.
Target Intelligence Brief
Metro International Biotech (MetroBiotech) holds "the most comprehensive portfolio of proprietary NAD boosters in the world" within EdenRoc Sciences[1], with two disclosed pharmaceutical-grade assets: MIB-626, a patented crystalline β-nicotinamide mononucleotide (NMN) with three completed or active Phase 2 studies[2]; and MIB-725, a next-generation NAD+ precursor in Phase 1 first-in-human dose-escalation[3]. The asset is structurally distinguished from the consumer-supplement NAD-booster category (ChromaDex's NIAGEN nicotinamide riboside; Elysium Health's Basis) by (i) pharmaceutical-grade IND development rather than DSHEA dietary-supplement pathway; (ii) indication-anchored clinical-trial design with disclosed NCT registrations in Friedreich's ataxia, post-COVID-19 acute kidney injury, exercise capacity, and metabolic flux[2,3,4,5,6]; (iii) EdenRoc-level shared-equity structure incentivizing cross-portfolio collaboration with sibling companies (Cantata Bio, Liberty Biosecurity, UpRNA, Revere Biosensors, Astrea Forensics, Claret Bioscience, Delavie Sciences)[1]; and (iv) a scientific advisory board anchored on David Sinclair, Johan Auwerx, Li-Huei Tsai, and other named NAD-biology principals[7]. Diligence focuses on indication-trajectory triage, competitive class differentiation, and the regulatory pathway separation from the consumer-supplement category.
§01 · Identity & biology
CompleteMechanism class. Both MIB-626 and MIB-725 act as exogenous NAD+ precursors, raising intracellular NAD+ to restore sirtuin (SIRT1/SIRT3) and PARP enzymatic activity, with downstream effects on mitochondrial biogenesis, DNA-damage response, and metabolic homeostasis. The pharmacological rationale derives from the well-documented age-associated and disease-associated decline in NAD+ tissue concentration[7].
source · MetroBiotech · NAD+ biology references
MIB-626 disclosure. Described publicly as "a novel, patented crystalline NAD+ booster with scalable manufacturing capabilities" — the crystalline form is the load-bearing IP and CMC differentiator vs. amorphous NMN sold as a supplement. Early human trials of MIB-626 are reported as showing "up to 200% increase in NAD+ levels within 14 days, without any drug-related serious adverse events".[1]
source · metrobiotech.com · verbatim
MIB-725 disclosure. Described publicly as "a next-generation NAD+ precursor", with Phase 1 single-ascending-dose study (
NCT06815991) initiated for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults[3]. Primary completion December 2026.source · ClinicalTrials.gov · NCT06815991
Figure A · NAD⁺ biosynthesis · pharmaceutical targets vs. supplement targets
[1] MetroBiotech, company website. metrobiotech.com (accessed 26 May 2026).
[7] NAD+ decline and sirtuin-mediated aging biology synthesized from extensive peer-reviewed literature. Primary reference: PubMed search "NAD+ sirtuin aging mitochondrial" — pubmed.ncbi.nlm.nih.gov.
§02 · Composite scoring
Complete · methodology-attributedFoster Rx Thesis composite renders the four-axis profile under methodology_id: foster_rx.composite_score.v1. Each axis carries a pattern-anchored estimate with explicit gap caveats; axes are not a substitute for primary diligence.
methodology · foster_rx.composite_score.v1
Figure B · Composite profile · v1 methodology
Mechanism plausibility — material. NAD+ depletion as a substrate-limited cofactor problem is one of the most published-on biological hypotheses of the past two decades, anchored on the Sinclair, Auwerx, and Tsai bodies of work — all three of whom serve on MetroBiotech's scientific advisory board[7]. The diligence question is not "is the mechanism real" — it is "does NAD+ elevation translate to disease-modifying clinical effect at tolerable systemic exposure."
composite axis · mechanism plausibility
Clinical evidence — workable. Five disclosed NCT registrations across four conditions (healthy metabolic flux, Friedreich's ataxia, COVID-19-associated AKI, exercise capacity) plus the MIB-725 Phase 1 (Table A below). Two trials completed (Friedreich's ataxia in May 2022; COVID-19/AKI in August 2023); readouts not yet correlated with go/no-go indication declaration in public materials.[2,3,4,5,6]
composite axis · clinical evidence
IP & CMC posture — material. The patented crystalline NMN form is the load-bearing differentiator. Crystallinity matters in two ways: (i) it supports IND-grade pharmaceutical CMC standards (USP characterization, polymorphic stability, bioavailability reproducibility) that amorphous supplement-grade NMN cannot match, and (ii) it underwrites composition-of-matter IP that does not depend on use-claim language vulnerable to §101 challenges. See §17 for landscape detail.
composite axis · IP & CMC
Indication-trajectory clarity — insufficient · narrow gap. Multiple Phase 2 readouts are available or imminent (Friedreich's ataxia completed 2022; COVID-19/AKI completed 2023; exercise study completed June 2025 per
NCT05878119) but the public materials do not yet declare a lead indication for pivotal advancement. This is the dominant diligence question: which indication, on what timeline, with what registration pathway.flagged · indication-trajectory question
§07–§08 · ADMET & pathways
Complete · class-levelADMET, class-level. NMN bioavailability is bounded by intestinal Slc12a8 transporter saturation and rapid first-pass conversion to nicotinamide. The MIB-626 crystalline form supports controlled dissolution and is described publicly as achieving "up to 200% increase in NAD+ levels within 14 days, without any drug-related serious adverse events" in early human studies[1]. Sustained tissue NAD+ elevation is the binding pharmacological question; the supplement-class NR molecules face the same constraint and report comparable acute pharmacodynamic profiles in published trials.
source · MetroBiotech · NAD biosynthesis literature
Pathway alignment. NMN → NAD+ → SIRT1/3 (mitochondrial deacetylase activity) → PGC-1α-mediated mitochondrial biogenesis is the canonical mechanism most relevant to muscle, kidney, and metabolic indications. SIRT1 → p53 axis and PARP-mediated DNA-damage response is the canonical mechanism most relevant to neurodegenerative and aging indications. Both are operative in the disclosed indication set.
computed · Foster Rx synthesis of public NAD literature
§11 · Expression of NAD biosynthesis enzymes
Complete · framework-levelNAD biosynthesis enzyme expression (NAMPT, NMNAT1/2/3, NRK1/2) is tissue-distributed and shows age-associated decline in kidney, muscle, and CNS — the three tissue systems represented in MetroBiotech's disclosed indication footprint. NAMPT decline in particular has been associated with mitochondrial dysfunction in age-related kidney and skeletal-muscle pathology, providing the upstream rationale for exogenous NMN supplementation. Tissue-distribution data is well-published; not rendered as a separate panel.
computed · public NAD literature
§15 · Disclosed pipeline · NCT-registered programs
CompleteFive clinical-trial registrations are public on ClinicalTrials.gov for Metro International Biotech-sponsored studies. Table A enumerates them with NCT, indication, phase, status, and primary completion date. The pattern is consistent with mechanism-driven indication exploration rather than single-indication conviction pivotalization — characteristic of a substrate-class therapeutic in mid-clinical-development.
source · ClinicalTrials.gov · sponsor query
| NCT | Compound | Indication | Phase | Status | Primary completion | Source |
|---|---|---|---|---|---|---|
NCT06882096 | NAD precursors | Metabolic flux in healthy adults (young vs. older) | 1 | Recruiting | Dec 2026 | [2] |
NCT06815991 | MIB-725 | Single ascending dose · safety/PK/PD in healthy adults | 1 | Recruiting | Dec 2026 | [3] |
NCT05878119 | MIB-626 | NMN with/without high-intensity exercise training | 2 | Completed | Jun 2025 | [4] |
NCT05038488 | MIB-626 | COVID-19 with stage 1 acute kidney injury | 2a | Completed | Aug 2023 | [5] |
NCT04817111 | NAD precursors | Friedreich's ataxia | 2a | Completed | May 2022 | [6] |
Pattern interpretation. Three completed Phase 2 studies (exercise/muscle, COVID-19/AKI, Friedreich's ataxia) constitute a triage portfolio across the canonical NAD+ tissue indications. Two ongoing Phase 1 studies (metabolic flux, MIB-725 dose escalation) extend the pharmacological characterization. The diligence question is which Phase 2 readout produced the most actionable effect-size signal and what registration pathway (orphan indication, accelerated, traditional) the lead program will pursue.
computed · Foster Rx synthesis · ClinicalTrials.gov data
Figure D · Five disclosed NCT registrations · 3 completed Ph 2 across NAD+ tissue indications + 2 active Ph 1
[2] NCT06882096 · ClinicalTrials.gov · clinicaltrials.gov/study/NCT06882096
[3] NCT06815991 · ClinicalTrials.gov · clinicaltrials.gov/study/NCT06815991
[4] NCT05878119 · ClinicalTrials.gov · clinicaltrials.gov/study/NCT05878119
[5] NCT05038488 · ClinicalTrials.gov · clinicaltrials.gov/study/NCT05038488
[6] NCT04817111 · ClinicalTrials.gov · clinicaltrials.gov/study/NCT04817111
§15.1 · Scientific advisory & KOL anchor
CompleteThe scientific advisory board, as publicly named, anchors on the most-cited principals of NAD-biology research: David Sinclair, A.O., Ph.D. (Harvard Medical School · sirtuin / NAD aging), Johan Auwerx, M.D., Ph.D. (EPFL · mitochondrial sirtuin biology), Li-Huei Tsai, Ph.D. (MIT · neurodegeneration / NAD), with additional anchors in Rajendra Apte, M.D., Ph.D. (Washington University · retinal aging), James Ellis, Ph.D., Nick Lane, Ph.D. (UCL · mitochondrial bioenergetics), Jeffrey Lieberman, M.D., and Lindsay Wu, Ph.D. (UNSW · NAD therapeutics). This is a category-defining KOL anchor for the NAD-booster class and is materially differentiating vs. supplement-class competitors that do not publish through equivalent academic networks.[1]
source · MetroBiotech · scientific advisory
§16 · Competitive landscape · NAD+ booster class
CompleteThe NAD+ booster competitive set bifurcates cleanly along regulatory pathway: pharmaceutical-grade IND development (MetroBiotech) vs. consumer dietary supplements under DSHEA (ChromaDex's NIAGEN nicotinamide riboside; Elysium Health's Basis NR/pterostilbene formulation). The two categories are differentiated by indication-anchored clinical-trial design, manufacturing/CMC discipline, and labeling/marketing constraints — not by underlying mechanism.
computed · Foster Rx synthesis
Figure E · DSHEA supplement pathway vs. FDCA/IND pathway · MetroBiotech occupies the right branch
| Comparator | Compound class | Regulatory pathway | Commercial channel | Stage | Source |
|---|---|---|---|---|---|
| MetroBiotech | NMN (crystalline) · novel precursors | IND · Rx pharmaceutical | Disease indications · prescription | Ph 2 | [1,2-6] |
| ChromaDex / NIAGEN | Nicotinamide riboside (NR) | DSHEA dietary supplement · NDI | Consumer · DTC supplement | Market | [8] |
| Elysium Health (Basis) | NR + pterostilbene | DSHEA dietary supplement | Consumer · DTC subscription | Market | [9] |
| Mitobridge → Astellas | Mitochondrial-pathway small molecules (acquired 2018) | IND pathway (Astellas internal) | Subsumed into Astellas pipeline | — | [10] |
Strategic interpretation. The category structurally favors MetroBiotech on three vectors: (i) indication-anchored claims (DSHEA prohibits supplement marketers from claiming disease modification — MetroBiotech's IND pathway permits indication-specific labeling on approval); (ii) reimbursement (consumer supplements are out-of-pocket; Rx pharmaceuticals are covered, materially expanding the addressable population); and (iii) CMC moat (crystalline-form patent + pharmaceutical-grade manufacturing capability are step-function barriers vs. supplement-grade amorphous synthesis).[1]
computed · Foster Rx synthesis
The diligence question — Astellas precedent. Astellas's 2018 acquisition of Mitobridge set a comparable anchor for late-stage mitochondrial-pathway small-molecule M&A in this class. Pricing terms are partially public[10]. The diligence step is to model MetroBiotech's pivotal-stage valuation envelope against Astellas/Mitobridge as the anchoring comparable.
flagged · comparable-anchored valuation
Figure F · Astellas/Mitobridge as comparable-anchored valuation precedent · MetroBiotech Phase 2 portfolio building toward pivotal-stage M&A inflection
[8] ChromaDex Corp. / Tru Niagen (nicotinamide riboside) — consumer dietary supplement positioning. Public corporate disclosures and product materials. chromadex.com.
[9] Elysium Health, Basis product (NR + pterostilbene). elysiumhealth.com — references "16+ ongoing or completed human clinical trials," consumer supplement positioning.
[10] Astellas Pharma / Mitobridge acquisition (2018). Public Astellas corporate disclosures. astellas.com/en/news.
§17 · Patents landscape · NAD+ booster class
Complete · framework-levelUSPTO public records surface multiple assignments in the NAD+ precursor and crystalline-form space; primary counsel-led search is required for asset-specific freedom-to-operate analysis. The composition-of-matter pathway via crystalline-form patenting is the dominant IP class for this asset, and is materially stronger than use-claim or formulation-claim approaches under post-Mayo/Myriad §101 jurisprudence. Table C frames the IP classes relevant to the diligence.
source · USPTO public search framework
| Claim class | Strength under post-2014 §101 jurisprudence | MetroBiotech alignment | Source |
|---|---|---|---|
| Composition-of-matter · novel crystalline form | Strong · physical-form claims survive Mayo/Myriad | Aligned · crystalline NMN claim disclosed publicly | [1] |
| Composition-of-matter · novel chemical entity (e.g., MIB-725 next-gen precursor) | Strong · NCE claims most defensible | Aligned · MIB-725 disclosed as next-gen precursor under Phase 1 IND | [3] |
| Method-of-treatment · use claims for established indications | Moderate · vulnerable to obviousness and §101 challenges depending on indication novelty | Indication-specific scope requires counsel review | USPTO |
| Process-of-manufacture · scalable crystalline synthesis | Strong · process claims defensible if non-obvious | Public materials reference "scalable manufacturing capabilities"[1] | [1] |
Counsel-led search required. Foster Rx does not render asset-specific FTO conclusions from public assignment search alone. The diligence pathway is (a) USPTO assignee variants ("Metro International Biotech," "MetroBiotech," "EdenRoc," named-inventor variants), (b) PCT applications, (c) sibling-portfolio cross-assignments (UpRNA, Cantata Bio), (d) competitor-side composition-of-matter blocking patents in the NMN/NR space.
flagged · counsel review required
§18 · Regulatory precedent
CompleteThe category regulatory bifurcation. The NAD+ booster space is the cleanest case study available of a single mechanistic class operating under two non-overlapping regulatory regimes — DSHEA (Dietary Supplement Health and Education Act) for the consumer-supplement competitors and FDCA/IND for MetroBiotech. The MIB-626 path through FDA IND is well-established procedurally; the binding regulatory question is which indication clears the pivotal pathway first and whether any qualifies for orphan, fast-track, or accelerated designation.
computed · FDA framework
Friedreich's ataxia precedent (
NCT04817111, completed May 2022). Friedreich's ataxia is an orphan-designation-eligible indication with mitochondrial pathophysiology directly aligned to NAD+ rescue mechanism. The completed Phase 2a is a registration-relevant data point for any pivotal-pathway decision in this indication. Specific orphan designation status under public OOPD records requires direct verification.[6]source · NCT04817111 · FDA OOPD framework
§22 · Standard of care & unmet need · per indication
Complete · framework-levelFriedreich's ataxia. Omaveloxolone (Reata, approved Feb 2023) established first-line precedent in this indication and the regulatory pathway is paved. Unmet need remains substantial across the patient population; mechanism diversification (Nrf2 pathway vs. NAD+ rescue) supports a parallel-asset hypothesis. Standard of care otherwise: symptomatic and supportive.
computed · FDA approvals · public literature
Post-COVID acute kidney injury (NCT05038488). AKI represents a high-mortality acute-care indication where no NAD-targeted therapy is approved. The Phase 2a completion (August 2023) is the most clinically-actionable acute indication in the disclosed portfolio, though pivotal pathway clarity is not public.
source · NCT05038488 · FDA framework
Exercise capacity / muscle (NCT05878119). Standard-of-care exercise interventions are first-line for muscle decline; a pharmacological adjunct claim is a complex regulatory framing — likely supplement-adjacent rather than disease-modifying registration. Strategic question: does MetroBiotech position this readout as supportive PD data or as an indication-pivot candidate.
computed · Foster Rx synthesis
§24 · Funding & EdenRoc structural advantage
Complete · framework-levelHolding-company model. EdenRoc operates as a parent providing centralized support: "a small group of personnel at the parent (EdenRoc) level, who support core business functions including legal, human resources, benefits, accounting, finance, IT, and business planning." Subsidiaries are autonomous but cross-pollinated via EdenRoc-level equity grants: "employees and advisors are granted equity at the EdenRoc level. The result is a cooperative group of start-ups, each working for the benefit of all."[1]
source · edenrocsciences.com · verbatim
The shared-equity strategic implication. A cross-portfolio equity grant materially differs from sibling-company-as-separate-asset financing in three respects: (i) it incentivizes cross-program scientific collaboration without requiring intercompany licensing transactions, (ii) it aligns advisor and operator interests across the portfolio (Sinclair, Auwerx, and other named SAB members likely hold EdenRoc-level equity), and (iii) it complicates the diligence picture — Metro-specific cap table cannot be evaluated without the broader EdenRoc cap-table context.
computed · Foster Rx synthesis
Figure C · EdenRoc portfolio · Metro highlighted as NAD+ Rx clinical-stage asset
§05 · §13 · §20 · §21 · §23 · Sections requiring sponsor disclosure
Evidence insufficient · NDA-bounded
Gap · proprietary CMC, cell-line, and commercial data outside public domain
INACCESSIBLE_DATA · sponsor disclosure under CDA · composite includes TIER_3_PARTNER_PENDING · partners: Elucidata (§13 multi-omics depth) · MMIT (§23 payer feasibility)
Chemical starting points (§05), cell-line essentiality (§13), GMP manufacturing detail beyond crystalline-form patent reference (§20), pricing and gross-to-net commercialization economics (§21), and per-indication payer-feasibility envelope (§23) are not available in public materials and would require sponsor disclosure under CDA. Foster Rx renders these as bounded gaps rather than fabricating estimates from absence of data. §13 cell-line essentiality additionally awaits Elucidata partner activation for systematic multi-omics depth; §23 payer feasibility awaits MMIT partner activation for reimbursement analytics.
Source manifest · consolidated
- Metro International Biotech, company website — https://www.metrobiotech.com/
- NCT06882096 · NAD precursor metabolic flux · ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT06882096
- NCT06815991 · MIB-725 Phase 1 SAD · ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT06815991
- NCT05878119 · MIB-626 + exercise · ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT05878119
- NCT05038488 · MIB-626 in COVID-19 / AKI · ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT05038488
- NCT04817111 · NAD precursor in Friedreich's ataxia · ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT04817111
- EdenRoc Sciences, portfolio holding structure — https://edenrocsciences.com/
- ChromaDex Corp. / Tru Niagen — https://www.chromadex.com/
- Elysium Health, Basis product — https://www.elysiumhealth.com/
- Astellas Pharma · Mitobridge acquisition (2018) — https://www.astellas.com/en/news
- PubMed search · NAD+ sirtuin aging mitochondrial — https://pubmed.ncbi.nlm.nih.gov/
- USPTO Patent Public Search — https://ppubs.uspto.gov/
Force11 citation block · v1.6 B.2 envelope extension
[1] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.metrobiotech.com/
- publication_date
- 2026-05-26
- title
- [not specified in source]
- publisher
- Metro International Biotech
- version
- as accessed 26 May 2026
- access_url
- https://www.metrobiotech.com/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[7] NAD+ sirtuin aging mitochondrial
- authors
- [not specified in source]
- persistent_id
- https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+sirtuin+aging+mitochondrial
- publication_date
- accessed 26 May 2026
- title
- NAD+ sirtuin aging mitochondrial
- publisher
- U.S. National Library of Medicine · PubMed
- version
- as accessed 26 May 2026
- access_url
- https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+sirtuin+aging+mitochondrial
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[2] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT06882096
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT06882096
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[3] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT06815991
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT06815991
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[4] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT05878119
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT05878119
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[5] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT05038488
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT05038488
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[6] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT04817111
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT04817111
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[8] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.chromadex.com/
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ChromaDex Corporation
- version
- as accessed 26 May 2026
- access_url
- https://www.chromadex.com/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[9] 16+ ongoing or completed human clinical trials,
- authors
- Elysium Health
- persistent_id
- https://www.elysiumhealth.com/
- publication_date
- accessed 26 May 2026
- title
- 16+ ongoing or completed human clinical trials,
- publisher
- Elysium Health
- version
- as accessed 26 May 2026
- access_url
- https://www.elysiumhealth.com/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[10] [not specified in source]
- authors
- Astellas Pharma
- persistent_id
- https://www.astellas.com/en/news
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- Astellas Pharma
- version
- as accessed 26 May 2026
- access_url
- https://www.astellas.com/en/news
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
Translational Confidence Score · v1.5 decomposition
TCS · computation pending
Section coverage
Share of the 25 brief sections at
CERTIFIED status — vs. EVIDENCE_INSUFFICIENT, NO_DATA_AVAILABLE, PARTIAL. Counts honest-emptiness gap_explanations as accounted-for, not as silent drops.pending
Posterior tightness
Calibration variance per certified claim — derived from L̂(Gₜ) tracked against the resolved outcome subset. Tightens as |Oₜ| (the outcome history) grows.
pending
Methodology quality
Aggregate validation grade across registered methodologies M — anchored on Inv₆ non-regression gate (validation against held-out fixtures before registration in M_t).
pending
Reproducibility signal
Outcome-anchoring fidelity — how reliably prediction-outcome pairs (c, o) in O reconcile within expected lag τ. Slow-timescale measurement; meaningful once outcome corpus depth is non-trivial.
pending
Envelope · publicly verifiable
- Methodology manifest
- foster_rx.composite_score.v1 · foster_rx.evidence_bounding.v1
- Source manifest hash
- sha256:9f1a…live-demo · 12 sources · 0 fabricated
- Status
- 25 sections · 9 complete · 1 bounded EI (5 axes grouped) · therapeutic-class scoring active
- Signature
- ed25519:demo-preview · pre-publication · not certified
- Date
- 26 May 2026 · live demo rendering
Commercialization Snapshot
Basking Biosciences
Evidence depth
Strong
clinical-stage signals, RAISE Phase 2 progress, investigator depth
Adequate
funding history, KOL network
Thin
manufacturing scale, payer feasibility, commercial economics
Commercialization signal
Tier-1 venture lead (ARCH Venture Partners)
Decision-ready
CEO transition Oct 2025 (Julia C. Owens)
Phase 2 Part B dosing underway
Open questions
3 questions requiring sponsor disclosure
- RAISE trial readout timeline & primary endpoint sensitivity
- RNA aptamer manufacturing scale-up economics
- Patent runway vs. tPA / tenecteplase comparable IP
Comparable benchmarks
acute ischemic stroke standard of care
Foster Rx renders evidence. The institutional decision is yours.
Commercialization Scorecard
Basking Biosciences is a clinical-stage biopharmaceutical company developing what would be, if approved, the first reversible thrombolytic therapy for acute ischemic stroke[1]. The asset architecture pairs BB-031, an RNA aptamer that inhibits von Willebrand Factor (vWF)-mediated platelet aggregation, with BB-025, a direct-acting reversal agent enabling "rapid and durable neutralization"[1]. The diligence-relevant facts are (i) the Phase 2 RAISE trial (
NCT06226805) is recruiting, enrolling toward 228 patients across 23 trial sites in the US, Australia, and Canada, with first patients dosed September 2025 and primary completion estimated June 2027[2]; (ii) the company has raised approximately $87.9M cumulatively across three disclosed rounds — $5.4M seed (December 2020)[3], $55M ARCH-led Series A (January 2024)[4], and a $27.5M financing tranche (October 2025) announced concurrently with the appointment of Julia C. Owens, Ph.D. as CEO[5]; (iii) the BB-025 reversal-agent Phase 1 first-in-human dosing initiated November 2025[6]; (iv) Lance Berman, MBChB, MS appointed CMO May 2026[7]. The architecturally interesting facts are the academic-origin pathway through OSU Wexner Medical Center, the comparable-anchored patent valuation methodology applied to anti-vWF aptamer IP, and the differentiated reversibility posture vs. the established thrombolytic standard of care (alteplase, tenecteplase, mechanical thrombectomy).
§01 · Identity, mechanism, and asset architecture
CompleteMechanism class. BB-031 is an RNA aptamer that binds the A1 domain of von Willebrand Factor (vWF), the multimeric plasma glycoprotein that bridges platelets to exposed subendothelial collagen and to glycoprotein Ib (GPIb) on the platelet surface. By inhibiting vWF–GPIb engagement, BB-031 prevents and reverses platelet-rich thrombus formation in flow conditions characteristic of arterial circulation — the pathophysiology of acute ischemic stroke. Unlike fibrin-targeting thrombolytics (alteplase, tenecteplase), the mechanism does not directly cleave fibrin; it interrupts the platelet-aggregation arm of arterial thrombus formation and stabilization.[1,8]
source · baskingbiosciences.com · vWF / aptamer literature
The reversibility differentiator. The asset is paired with BB-025, a complementary reversal agent that binds BB-031 directly, neutralizing its inhibitory activity. Reversibility is the load-bearing differentiator vs. all approved thrombolytics — alteplase (tPA) and tenecteplase have no direct antidote, and bleeding-conversion risk is the single largest driver of treatment-eligibility constriction in acute ischemic stroke. A reversible thrombolytic structurally expands the eligible-patient envelope by lowering the worst-case scenario for the treating clinician.[1]
computed · Foster Rx synthesis · public literature
Figure A · BB-031 mechanism · vWF–GPIb inhibition with BB-025 reversal
[1] Basking Biosciences, company website. baskingbiosciences.com (accessed 26 May 2026).
[8] Nimjee laboratory publications on anti-vWF aptamers and reversal-agent design. PubMed: pubmed.ncbi.nlm.nih.gov/?term=Nimjee+vWF+aptamer.
§02 · Composite scoring
Complete · methodology-attributedFoster Rx Thesis composite renders under methodology_id: foster_rx.composite_score.v1. Patent landscape sub-axis additionally renders under methodology_id: foster_rx.patent_valuation.v1 using comparable-anchored estimation — the demonstration moment for the methodology-attribution discipline.
methodology · foster_rx.composite_score.v1 + foster_rx.patent_valuation.v1
Figure B · Composite profile · v1 methodology
Mechanism & unmet need fit — material. Acute ischemic stroke is the second-leading cause of death globally and a top-five cause of long-term disability. Standard-of-care thrombolytic intervention (alteplase, tenecteplase) reaches a small fraction of eligible patients due to a combination of treatment-window constraints (4.5 hours for alteplase) and contraindication-driven exclusion. A first-in-class reversible thrombolytic — by lowering the worst-case scenario of bleeding conversion — structurally expands the eligible-patient envelope. This is the most material clinical-impact differentiation in this category in the past decade.[9]
composite axis · mechanism & unmet need fit
Clinical evidence — workable. Phase 2 RAISE is recruiting with disciplined design: two-part SAD (Part A up to 48 patients, 3:1 randomization across ascending doses; Part B ~180 patients at selected doses). Primary completion June 2027 estimated. First patients dosed September 2025; Part B dosing announced concurrent with the October 2025 financing tranche. The 23-site, three-country (US, Australia, Canada) footprint is appropriate scale for a Phase 2 stroke-trial readout.[2,5]
composite axis · clinical evidence
Capital structure — material. Cumulative ~$87.9M raised across three disclosed tranches — $5.4M seed (Dec 2020), $55M ARCH-led Series A (Jan 2024), $27.5M tranche (Oct 2025). ARCH Venture Partners leadership is a tier-1 signal for clinical-stage biotech. Tranching aligned to clinical milestones (Part B dosing concurrent with the Oct 2025 close) suggests disciplined capital discipline by the syndicate.[3,4,5]
composite axis · capital structure
Patent posture — workable · comparable-anchored. Rendered under methodology_id: foster_rx.patent_valuation.v1: comparable-anchored estimation across the anti-vWF aptamer IP class, with USPTO Patent Public Search as primary source and Nimjee laboratory + OSU/OSIF assignment search as institutional-origin anchor. This is a methodology-attribution demonstration moment; specific assignment search outputs render in §17.
composite axis · patent posture · methodology attributed
§03–§07 · Small-molecule drugability axes
Evidence insufficient · modality mismatch
Gap · RNA aptamer modality outside small-molecule drugability frameworks
METHODOLOGY_GAP · small-molecule drugability methodology does not score RNA aptamer modality; composite-score returns
not_applicable rather than insufficient for these axes
Sections §03 drugability, §04 probe chemistry, §05 chemical starting points, §06 selectivity, and §07 ADMET are scoped to small-molecule programs and reference CanSAR, Probe Miner, and Open Targets drugability scores. BB-031 is an RNA aptamer; its PK/PD and stability are governed by oligonucleotide chemistry (modified-nucleotide stability, plasma half-life, RES clearance) rather than by CYP-mediated metabolism. The composite-score methodology treats these axes as not_applicable for the aptamer modality and proceeds to the aptamer-relevant pharmacology (§08 below) and the clinical evidence (§02 / §15). This is the correct rendering for the asset class.
§08 · Hemostasis & thrombosis pathway alignment
CompletevWF is the canonical bridge between exposed subendothelial collagen (vessel injury) and platelet adhesion (GPIb-mediated tethering, then GPIIb/IIIa-mediated aggregation). Arterial thrombosis — high shear, platelet-rich — is governed by the vWF–GPIb axis, distinguishing it from venous thrombosis (fibrin-dominant). BB-031's pharmacological action is precisely targeted to the arterial-thrombosis arm via vWF A1-domain antagonism, which is the canonical published biology[8,10].
source · hemostasis literature · Nimjee laboratory
§15 · Phase 2 RAISE trial · structure & status
CompleteThe RAISE trial (
NCT06226805) is a multicenter, double-blinded, placebo-controlled, single ascending dose, two-part, randomized Phase 2 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BB-031 in acute ischemic stroke patients[2].source · ClinicalTrials.gov · NCT06226805
Figure C · RAISE Phase 2 trial design · two-part SAD
| Parameter | Value | Source |
|---|---|---|
| Trial identifier | NCT06226805 (RAISE) | [2] |
| Phase | Phase 2 | [2] |
| Indication | Acute Ischemic Stroke | [2] |
| Intervention | BB-031 · single IV bolus dose | [2] |
| Sponsor | Basking Biosciences, Inc. | [2] |
| Planned enrollment | 228 patients total | [2] |
| Part A · dose escalation | Up to 48 participants · 3:1 drug-to-placebo · 3 ascending dose cohorts | [2] |
| Part B · expansion | ~180 participants · selected doses from Part A | [2] |
| Number of sites | 23 locations · US, Australia, Canada | [2] |
| Study start (actual) | 31 July 2024 | [2] |
| First patients dosed | 10 September 2025 | [11] |
| Part B dosing announcement | 22 October 2025 | [5] |
| Primary completion (estimated) | June 2027 | [2] |
| Current status | Recruiting | [2] |
[2] NCT06226805 · ClinicalTrials.gov — clinicaltrials.gov/study/NCT06226805
[11] Basking Biosciences press release · "Phase 2 Trial First Patients Dosed" · 10 September 2025 — baskingbiosciences.com/news/
§15.1 · Investigator network & institutional anchor
CompleteCo-founder & clinical anchor. Shahid Nimjee, M.D., Ph.D. — Professor of Neurosurgery at The Ohio State University Wexner Medical Center — is Basking's co-founder, Chief Scientific Officer, and Stroke Clinical Lead. The Nimjee Laboratory at OSU Wexner is publicly described as "focused on evaluating anti-vWF aptamers", anchoring the asset directly to its academic-origin laboratory through ongoing investigator involvement.[1]
source · baskingbiosciences.com · leadership
Trial footprint & geographic scope. 23 RAISE trial sites span the US, Australia, and Canada[2]. International-investigator distribution at Phase 2 is meaningfully differentiating — it signals (i) site-recruitment confidence by the operations team, (ii) regulatory positioning supportive of multi-region eventual filings, and (iii) investigator-network depth reaching beyond the OSU/US-only academic core. Specific site list and site-level enrollment requires direct disclosure.
source · NCT06226805 · sites field
Figure E · RAISE investigator network · OSU Wexner anchor with 23-site multi-region distribution (US + Canada + Australia)
§16 · Competitive landscape · acute ischemic stroke therapeutics
CompleteThe acute ischemic stroke (AIS) therapeutic landscape is structured around two approved IV thrombolytics — alteplase (tPA) and tenecteplase — plus mechanical thrombectomy for large-vessel occlusion. None offers reversibility. The treatment-window and contraindication constraints together exclude the vast majority of AIS patients from acute pharmacological intervention. Table B summarizes the comparator set.
computed · FDA labeling · AHA/ASA guidelines
| Therapy | Mechanism | Treatment window | Reversibility | Major limitation | Source |
|---|---|---|---|---|---|
| Alteplase (tPA) | Recombinant tissue plasminogen activator · fibrin lysis | ≤ 4.5 hours from onset | None | Symptomatic intracranial hemorrhage risk; narrow window | [12] |
| Tenecteplase | Modified tPA · fibrin lysis | ≤ 4.5 hours (per AHA/ASA 2024 update) | None | Same hemorrhagic risk class; off-label in some jurisdictions | [12] |
| Mechanical thrombectomy | Endovascular clot retrieval | Up to 24 hours (select large-vessel occlusion) | N/A (mechanical) | Requires comprehensive stroke center; LVO-only | [12] |
| BB-031 (Basking) | RNA aptamer · vWF A1-domain inhibition | TBD (Phase 2) | BB-025 direct reversal | First-in-class · Phase 2 ongoing | [1,2] |
Strategic interpretation. The therapeutic gap that BB-031 addresses is the bleeding-conversion ceiling that constrains the eligible-treatment fraction. A reversible thrombolytic does not need to demonstrate superior efficacy to alteplase to be commercially material — it needs to demonstrate non-inferior efficacy with materially lower bleeding-conversion risk, which (combined with the BB-025 direct reversal capability) would expand the treatable population. The Phase 2 RAISE design is appropriately scoped to characterize this risk/benefit envelope; it is not yet powered for pivotal regulatory claim.[2]
computed · Foster Rx synthesis
Figure F · Acute ischemic stroke comparator 2×2 · BB-031 + BB-025 in the extended-window + reversible white space
§17 · Patents landscape · comparable-anchored valuation
Complete · methodology-attributedMethodology attribution. Patent landscape rendered under methodology_id: foster_rx.patent_valuation.v1 — comparable-anchored estimation. This is the demonstration moment for the methodology-attribution discipline: rather than a single numerical estimate, the brief renders the inputs, the comparable anchors, and the estimation envelope, leaving counsel-led primary search as the binding deliverable.
methodology · foster_rx.patent_valuation.v1
Primary search framework. USPTO Patent Public Search across (i) assignee variants ("Basking Biosciences," "DTRI" — historical pre-name internal codename, BB-031 is also known as DTRI-031[2]), (ii) Ohio State University assignment search via OSIF (Ohio State Innovation Foundation), (iii) Nimjee inventor-name searches for foundational aptamer composition-of-matter and use-claim patents, (iv) PCT applications via WIPO Patentscope.
source · USPTO · WIPO · OSIF framework
Comparable anchors for valuation envelope. RNA aptamer therapeutic IP is a narrow comparable class. The most-cited public comparable is pegaptanib (Macugen, Pfizer/Eyetech, FDA-approved 2004) — the first RNA aptamer therapeutic approved by FDA. Pegaptanib's IP portfolio and post-approval valuation trajectory provide an anchor for analyzing how anti-vWF aptamer composition-of-matter claims may be valued at pivotal-stage transactions, with the caveat that the AIS indication and acute-administration profile are clinically and commercially distinct from pegaptanib's wet-AMD indication.
computed · pegaptanib comparable anchor
Counsel-led search required. Foster Rx does not render a numerical patent valuation from public assignment search alone. The deliverable scope is (i) the assignment landscape, (ii) the comparable-anchored envelope, (iii) the gaps requiring primary counsel review (FTO against competitor antiplatelet/thrombolytic IP, OSU/OSIF license-back economics, sublicense rights to BB-025). Specific valuation estimates require counsel-led primary search and term-sheet-level disclosure of the OSU/OSIF licensing agreement.
flagged · counsel review required
§18 · Regulatory precedent
CompleteAcute thrombolytic regulatory pathway. FDA approval precedents (alteplase 1996 for AIS, tenecteplase historical for MI then off-label/select-approval for AIS) establish the registrational framework for acute IV thrombolytic claims. Endpoints typically combine NIHSS improvement, mRS at 90 days, and symptomatic intracranial hemorrhage rate. A novel-mechanism reversible thrombolytic would likely require demonstration of (a) non-inferior efficacy vs. standard of care or vs. placebo (depending on eligibility population), and (b) materially improved bleeding-conversion profile sufficient to support label-eligibility expansion claims. The BB-025 reversal capability may also support a separate ancillary label claim.[12]
source · FDA labeling · AHA/ASA guidelines
§22 · Standard of care & unmet need · acute ischemic stroke
CompleteAcute ischemic stroke accounts for the majority of stroke cases globally; stroke is the second-leading cause of death and a top-five cause of long-term disability[9]. Per AHA stroke statistics, the fraction of AIS patients receiving acute pharmacological thrombolysis remains substantially below clinical-eligibility estimates, with treatment-window arrival logistics and bleeding-risk contraindications as the dominant exclusion factors. The reversibility differentiator of BB-031/BB-025 directly addresses the second of these constraints.
source · AHA stroke statistics
§24 · Funding history & leadership progression
CompletePublic funding disclosures total approximately $87.9M cumulatively across three named tranches, structured against clinical milestones. The October 2025 tranche was disclosed concurrently with the CEO transition — Richard Shea transitioning to President & COO, Julia C. Owens, Ph.D. appointed CEO. This pattern (tranching aligned to enrollment milestones, leadership professionalization at Phase 2 expansion) is consistent with disciplined ARCH-led clinical-stage syndicate behavior.[3,4,5]
source · Basking press releases
Figure D · Funding history & clinical milestones · 2020–2026
| Date | Amount | Disclosure | Source |
|---|---|---|---|
| Dec 2020 | $5.4M | Seed financing closed · development of reversible thrombolytic therapy | [3] |
| Jan 2024 | $55M | Series A · "led by ARCH Venture Partners" · funds Phase 2 RAISE trial of BB-031 | [4] |
| Sep 2025 | — | RAISE Phase 2 trial first patients dosed | [11] |
| Oct 2025 | $27.5M | Financing tranche · Julia C. Owens, Ph.D. appointed CEO · Richard Shea to President & COO · supports Part B execution and BB-025 Phase 1 launch | [5] |
| Nov 2025 | — | BB-025 reversal-agent Phase 1 first participants dosed | [6] |
| May 2026 | — | Lance Berman, MBChB, MS appointed Chief Medical Officer | [7] |
| ≈ $87.9M cumulative | Disciplined milestone-tranched, ARCH-led Series A as anchor financing | ||
[3] Basking Biosciences press release · "$5.4M Seed Financing Completed" · 7 December 2020 — baskingbiosciences.com/news/
[4] Basking Biosciences press release · "$55M Financing Close" · 30 January 2024 — ARCH Venture Partners-led — baskingbiosciences.com/news/
[5] Basking Biosciences press release · "Phase 2b Part B Dosing & $27.5M Financing Tranche · Julia C. Owens, Ph.D. CEO" · 22 October 2025 — baskingbiosciences.com/news/
[6] Basking Biosciences press release · "BB-025 Phase 1 First Participants Dosed" · 12 November 2025 — baskingbiosciences.com/news/
[7] Basking Biosciences press release · "Lance Berman Appointed Chief Medical Officer" · 4 May 2026 — baskingbiosciences.com/news/
§25 · Disease burden & sociodemographic context
Complete · framework-levelStroke is the second-leading cause of death globally and a leading cause of long-term adult disability; per AHA's annual Heart Disease and Stroke Statistics, the disease burden — combining direct medical, post-acute rehabilitation, and lost-productivity costs — places stroke among the highest-aggregate-cost CNS disease categories. Demographics are global, weighted toward older populations but with material under-65 burden; the AIS subtype dominates incidence relative to hemorrhagic stroke. The disease burden is the unmet-need amplifier behind the commercial thesis for any meaningful expansion of the eligible-treatment fraction.[9]
source · AHA · global stroke statistics
[9] American Heart Association · annual Heart Disease and Stroke Statistics Update — heart.org/en/about-us/heart-and-stroke-association-statistics
[10] Hemostasis & vWF biology · primary references via PubMed — pubmed.ncbi.nlm.nih.gov/?term=von+Willebrand+factor+platelet+thrombosis
[12] FDA labeling & AHA/ASA acute ischemic stroke guidelines — fda.gov · stroke.org/en/professionals/stroke-guidelines
§13 · §20 · §21 · §23 · Sections requiring sponsor disclosure
Evidence insufficient · NDA-bounded
Gap · proprietary cell-line, GMP, pricing, and payer data outside public domain
INACCESSIBLE_DATA · sponsor disclosure under CDA + OSU/OSIF license-back terms · composite includes TIER_3_PARTNER_PENDING · partners: Elucidata (§13 multi-omics depth) · MMIT (§23 payer feasibility)
Cell-line essentiality (§13), GMP oligonucleotide manufacturing scale and CDMO selection (§20), pricing and gross-to-net commercialization economics (§21), and per-indication payer-feasibility envelope (§23) are not available in public materials and would require sponsor disclosure under CDA. The OSU/OSIF license-back economics and any sublicense rights to BB-025 also fall in this category. Foster Rx renders these as bounded gaps rather than fabricating estimates. §13 cell-line essentiality additionally awaits Elucidata partner activation for systematic multi-omics depth; §23 payer feasibility awaits MMIT partner activation for reimbursement analytics.
Source manifest · consolidated
- Basking Biosciences, company website — https://www.baskingbiosciences.com/
- NCT06226805 · RAISE Phase 2 · ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT06226805
- Basking Biosciences press release · $5.4M Seed Financing (Dec 2020) — https://baskingbiosciences.com/news/
- Basking Biosciences press release · $55M Series A · ARCH-led (Jan 2024) — https://baskingbiosciences.com/news/
- Basking Biosciences press release · $27.5M tranche & Julia Owens CEO (Oct 2025) — https://baskingbiosciences.com/news/
- Basking Biosciences press release · BB-025 Phase 1 First Dosing (Nov 2025) — https://baskingbiosciences.com/news/
- Basking Biosciences press release · Lance Berman CMO Appointment (May 2026) — https://baskingbiosciences.com/news/
- PubMed · Nimjee anti-vWF aptamer publications — https://pubmed.ncbi.nlm.nih.gov/?term=Nimjee+vWF+aptamer
- American Heart Association · Heart Disease & Stroke Statistics — https://www.heart.org/en/about-us/heart-and-stroke-association-statistics
- PubMed · vWF biology / platelet thrombosis — https://pubmed.ncbi.nlm.nih.gov/?term=von+Willebrand+factor+platelet+thrombosis
- Basking Biosciences press release · Phase 2 Trial First Patients Dosed (Sep 2025) — https://baskingbiosciences.com/news/
- FDA labeling & AHA/ASA stroke guidelines — https://www.fda.gov/ · https://www.stroke.org/en/professionals/stroke-guidelines
- USPTO Patent Public Search — https://ppubs.uspto.gov/
- Ohio State Innovation Foundation (OSIF) — https://research.osu.edu/innovation-and-partnerships/innovation-and-commercialization
Force11 citation block · v1.6 B.2 envelope extension
[1] [not specified in source]
- authors
- Basking Biosciences
- persistent_id
- https://www.baskingbiosciences.com/
- publication_date
- 2026-05-26
- title
- [not specified in source]
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://www.baskingbiosciences.com/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[8] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://pubmed.ncbi.nlm.nih.gov/?term=Nimjee+vWF+aptamer
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- U.S. National Library of Medicine · PubMed
- version
- as accessed 26 May 2026
- access_url
- https://pubmed.ncbi.nlm.nih.gov/?term=Nimjee+vWF+aptamer
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[2] [not specified in source]
- authors
- ClinicalTrials.gov (U.S. National Library of Medicine)
- persistent_id
- https://clinicaltrials.gov/study/NCT06226805
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- ClinicalTrials.gov (U.S. National Library of Medicine)
- version
- as accessed 26 May 2026
- access_url
- https://clinicaltrials.gov/study/NCT06226805
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[11] Phase 2 Trial First Patients Dosed
- authors
- Basking Biosciences
- persistent_id
- https://baskingbiosciences.com/news/
- publication_date
- 2025-09-10
- title
- Phase 2 Trial First Patients Dosed
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://baskingbiosciences.com/news/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[3] $5.4M Seed Financing Completed
- authors
- Basking Biosciences
- persistent_id
- https://baskingbiosciences.com/news/
- publication_date
- 2020-12-07
- title
- $5.4M Seed Financing Completed
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://baskingbiosciences.com/news/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[4] $55M Financing Close
- authors
- Basking Biosciences
- persistent_id
- https://baskingbiosciences.com/news/
- publication_date
- 2024-01-30
- title
- $55M Financing Close
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://baskingbiosciences.com/news/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[5] Phase 2b Part B Dosing $27.5M Financing Tranche · Julia C. Owens, Ph.D. CEO
- authors
- Basking Biosciences
- persistent_id
- https://baskingbiosciences.com/news/
- publication_date
- 2025-10-22
- title
- Phase 2b Part B Dosing $27.5M Financing Tranche · Julia C. Owens, Ph.D. CEO
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://baskingbiosciences.com/news/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[6] BB-025 Phase 1 First Participants Dosed
- authors
- Basking Biosciences
- persistent_id
- https://baskingbiosciences.com/news/
- publication_date
- 2025-11-12
- title
- BB-025 Phase 1 First Participants Dosed
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://baskingbiosciences.com/news/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[7] Lance Berman Appointed Chief Medical Officer
- authors
- Basking Biosciences
- persistent_id
- https://baskingbiosciences.com/news/
- publication_date
- 2026-05-04
- title
- Lance Berman Appointed Chief Medical Officer
- publisher
- Basking Biosciences
- version
- as accessed 26 May 2026
- access_url
- https://baskingbiosciences.com/news/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[9] [not specified in source]
- authors
- American Heart Association
- persistent_id
- https://www.heart.org/en/about-us/heart-and-stroke-association-statistics
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- American Heart Association
- version
- as accessed 26 May 2026
- access_url
- https://www.heart.org/en/about-us/heart-and-stroke-association-statistics
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[10] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://pubmed.ncbi.nlm.nih.gov/?term=von+Willebrand+factor+platelet+thrombosis
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- U.S. National Library of Medicine · PubMed
- version
- as accessed 26 May 2026
- access_url
- https://pubmed.ncbi.nlm.nih.gov/?term=von+Willebrand+factor+platelet+thrombosis
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
[12] [not specified in source]
- authors
- [not specified in source]
- persistent_id
- https://www.fda.gov/
- publication_date
- accessed 26 May 2026
- title
- [not specified in source]
- publisher
- U.S. Food and Drug Administration
- version
- as accessed 26 May 2026
- access_url
- https://www.fda.gov/
- content_fingerprint
- demo-grade · UNF computation pending (Inv₈′)
Translational Confidence Score · v1.5 decomposition
TCS · computation pending
Section coverage
Share of the 25 brief sections at
CERTIFIED status — vs. EVIDENCE_INSUFFICIENT, NO_DATA_AVAILABLE, PARTIAL. Counts honest-emptiness gap_explanations as accounted-for, not as silent drops.pending
Posterior tightness
Calibration variance per certified claim — derived from L̂(Gₜ) tracked against the resolved outcome subset. Tightens as |Oₜ| (the outcome history) grows.
pending
Methodology quality
Aggregate validation grade across registered methodologies M — anchored on Inv₆ non-regression gate (validation against held-out fixtures before registration in M_t).
pending
Reproducibility signal
Outcome-anchoring fidelity — how reliably prediction-outcome pairs (c, o) in O reconcile within expected lag τ. Slow-timescale measurement; meaningful once outcome corpus depth is non-trivial.
pending
Envelope · publicly verifiable
- Methodology manifest
- foster_rx.composite_score.v1 · foster_rx.patent_valuation.v1 · foster_rx.evidence_bounding.v1
- Source manifest hash
- sha256:3b8e…live-demo · 14 sources · 0 fabricated
- Status
- 25 sections · 11 complete · 2 EI bundles (5 small-mol axes not_applicable; 4 axes NDA-bounded) · methodology-attribution discipline active in §02 / §17
- Signature
- ed25519:demo-preview · pre-publication · not certified
- Date
- 26 May 2026 · live demo rendering
The governance window is opening.
Four forces are aligning that make this the right window for an evidence-grade diligence architecture — and a narrow one for incumbents to respond from a non-architecturally-aligned starting point.
i.
Budget
Pharma AI governance budgets are line-iteming.
Every top-twenty pharma has stood up a formal AI governance function in the last twenty-four months. Vendor budgets structurally aligned with that function are forming now — not in eighteen months.
ii.
Regulation
EU AI Act enforcement is approaching.
Transparency posture and methodology disclosure are not optional for AI/ML in regulated life sciences. Foster Rx's architecture is structurally compliant with high-risk-system requirements. Black-box AI competitors are not.
iii.
Deal volume
The patent cliff is driving M&A.
Three-hundred-billion-dollar revenue at risk through 2030 is moving deal volume up and shortening evaluation windows. Faster, more defensible diligence is the binding constraint, not a luxury.
iv.
Architecture
Incumbents cannot ship this in twelve to eighteen months.
Claim-level attribution and signed-envelope verification require ground-up architectural commitment, not LLM integration. The estimated time-to-parity from incumbent intent to incumbent shipping is eighteen to thirty months. The window is open.
Three engagement shapes.
Different commitments at different durations, anchored on the same evidence-grade substrate.
Single-asset diligence engagement
Four to six weeks. Scope-bounded. Evidence-cited deliverable on a specific target, indication, or asset. Typical entry shape for a first engagement.
Ongoing diligence partnership
Quarterly cadence on an asset-portfolio basis. The architecture renders against your watchlist, your in-licensing funnel, or your sourced opportunity flow on a continuous basis.
Methodology partnership
For institutions that want to anchor their own internal diligence methodology in the Foster Rx architecture. Structured as a multi-quarter engagement with co-development of asset-class-specific methodology modules.
Pricing scoped in conversation. Mutual NDA is the first step.
If this resonates, here are three ways to engage. Pick the path that fits.